These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Targeted therapy in the treatment of metastatic renal cell cancer. Di Lorenzo G; Scagliarini S; Di Napoli M; Scognamiglio F; Rizzo M; Carteni' G Oncology; 2009; 77 Suppl 1():122-31. PubMed ID: 20130440 [TBL] [Abstract][Full Text] [Related]
3. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453 [TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach. Bukowski RM Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712 [TBL] [Abstract][Full Text] [Related]
5. Sequential use of targeted agents in the treatment of renal cell carcinoma. Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Yang CH; Chuang CK; Hsieh JJ; Chang JW Expert Opin Drug Saf; 2010 May; 9(3):459-70. PubMed ID: 20113155 [TBL] [Abstract][Full Text] [Related]
8. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979 [TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? Rini BI; Bukowski RM Oncology (Williston Park); 2008 Apr; 22(4):388-96; discussion 396, 402-3, 476 passim. PubMed ID: 18472614 [TBL] [Abstract][Full Text] [Related]
10. Management of metastatic renal cell carcinoma in the era of targeted therapies. Webber K; Cooper A; Kleiven H; Yip D; Goldstein D Intern Med J; 2011 Aug; 41(8):594-605. PubMed ID: 21627746 [TBL] [Abstract][Full Text] [Related]
11. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Oudard S; Elaidi RT Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686 [TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. Vano YA; Tartour E; Fournier LS; Beuselinck B; Mejean A; Oudard S Expert Rev Anticancer Ther; 2014 May; 14(5):523-42. PubMed ID: 24640949 [TBL] [Abstract][Full Text] [Related]